Rune Andreas Kroken
Overview
Explore the profile of Rune Andreas Kroken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Andreou D, Steen N, Jorgensen K, Smelror R, Wedervang-Resell K, Nerland S, et al.
Psychol Med
. 2022 Apr;
53(4):1479-1488.
PMID: 35387700
Background: Both neurodegenerative and neurodevelopmental abnormalities have been suggested to be part of the etiopathology of severe mental illness (SMI). Neuron-specific enolase (NSE), mainly located in the neuronal cytoplasm, may...
12.
Bjarke J, Gjerde H, Jorgensen H, Kroken R, Loberg E, Johnsen E
Acta Neuropsychiatr
. 2022 Mar;
34(5):282-288.
PMID: 35260218
Objective: Akathisia is among the most unpleasant side effects related to antipsychotic drug (AP) use, and possible associations between akathisia and agitation, depression and suicidal behaviour, respectively, have been described...
13.
Szabo A, OConnell K, Ueland T, Sheikh M, Agartz I, Andreou D, et al.
Brain Behav Immun
. 2021 Nov;
99:299-306.
PMID: 34758379
Background: Schizophrenia (SCZ) and bipolar disorder (BD) are severe mental illnesses (SMI) that are part of a psychosis continuum, and dysregulated innate immune responses have been suggested to be involved...
14.
Engh J, Ueland T, Agartz I, Andreou D, Aukrust P, Boye B, et al.
Schizophr Bull
. 2021 Sep;
48(1):37-46.
PMID: 34499169
Background: Immune dysfunction has been implicated in the pathogenesis of schizophrenia and other nonaffective psychosis (SCZ), bipolar spectrum disorder (BIP) and major depressive disorder (MDD). The cytokines B cell-activating factor...
15.
Stromme M, Mellesdal L, Bartz-Johannesen C, Kroken R, Krogenes M, Mehlum L, et al.
Schizophr Res
. 2021 Jul;
235:29-35.
PMID: 34303258
Background: In society at large, it is debated whether use of antipsychotic drugs is associated with increased or decreased mortality among patients with schizophrenia. Large register studies have demonstrated an...
16.
Sinkeviciute I, Hugdahl K, Bartz-Johannessen C, Kroken R, Loberg E, Kjelby E, et al.
J Clin Psychopharmacol
. 2021 May;
41(4):389-396.
PMID: 33938520
Background: Most studies investigating antipsychotic effectiveness report either total psychopathology or symptom cluster findings. Studies focusing on a separate symptom, such as hallucinations, a hallmark symptom in schizophrenia, are scarce.Therefore,...
17.
Beresniewicz J, Craven A, Hugdahl K, Loberg E, Kroken R, Johnsen E, et al.
Diagnostics (Basel)
. 2021 Jan;
11(1).
PMID: 33477803
The relation between auditory verbal hallucinations (AVH) and white matter has been studied, but results are still inconsistent. This inconsistency may be related to having only a single time-point of...
18.
Drosos P, Bronnick K, Joa I, Johannessen J, Johnsen E, Kroken R, et al.
J Clin Psychopharmacol
. 2020 Nov;
40(6):534-540.
PMID: 33136922
Background: Remission in schizophrenia is difficult to achieve. Antipsychotic drugs are critical in the treatment of schizophrenia. International guidelines for the pharmacological treatment of schizophrenia recommend a 3-step algorithm with...
19.
Tonnesen S, Kaufmann T, de Lange A, Richard G, Doan N, Alnaes D, et al.
Biol Psychiatry Cogn Neurosci Neuroimaging
. 2020 Aug;
5(12):1095-1103.
PMID: 32859549
Background: Schizophrenia (SZ) and bipolar disorder (BD) share substantial neurodevelopmental components affecting brain maturation and architecture. This necessitates a dynamic lifespan perspective in which brain aberrations are inferred from deviations...
20.
Lund-Heimark H, Kjelby E, Mehlum L, Gjestad R, Selbaek G, Kroken R, et al.
BJPsych Open
. 2020 Jun;
6(4):e63.
PMID: 32552924
Background: The common recommendation that adults with onset of mental illness after the age of 65 should receive specialised psychogeriatric treatment is based on limited evidence. Aims: To compare factors...